Upjohn's Rogaine self-selection studies praised by NDAC member.

Executive Summary

PHARMACIA & UPJOHN ROGAINE SELF-SELECTION STUDIES "FAIRLY GOOD," FDA Nonprescription Drugs Advisory Committee member Ralph D'Agostino, PhD, Boston University, said at a Nov. 17 joint meeting of NDAC and the Dermatologic and Ophthalmic Drugs Advisory Committee. Commenting on whether the company was able to show that consumers can accurately determine if their hair loss could be treated by OTC Rogaine given the information provided on the product label, D'Agostino described the firm's studies as "fairly good" and the results "pretty respectable."